bioinformatics

Following the recent expansion of Amazon Omics, as covered in our previous article “Ready, set, analyze: Amazon Omics unveils new Ready2Run workflows”, we wanted to explore the role of third-party providers in shaping the landscape of genomic analysis and bioinformatics. NVIDIA is one of these providers. The GPU company has worked to integrate their Parabricks…

Amazon Web Services (AWS) recently announced a significant expansion of Amazon Omics at the annual AWS Life Sciences Executive Symposium in Boston. Amazon Omics, which the company introduced last year, helps life science organizations to store, query and analyze genomic, transcriptomic and other omics data. While other tools such as Qlucore Omics Explorer, Genospace, StrandOmics,…

Biologics are changing the way we treat disease, affecting where companies invest and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) were biologics. Its partner agency — the agency’s Center for Biologics Evaluation and Research (CBER)—approved a dozen additional…

Diversity in clinical trials is crucial for ensuring that new medical treatments are safe and effective for all populations. Last year, the FDA released draft guidance that aims to improve the enrollment of historically underrepresented populations in clinical trials. Demand is growing for more transparency and diversity in clinical trials, according to Erin Leckrone, senior…

For all of its promise in healthcare and elsewhere, deploying artificial intelligence is frequently a challenging endeavor. “Close collaboration between data science teams, other project team members and stakeholders is essential,” said Jennifer Bradford, director of data science at Phastar, the London-headquartered contract research organization. While input from computational, statistical or medical experts could be…